Skip to content

Horizon BCBS

Does Horizon BCBS cover Wegovy?

It depends on your benefits. Horizon BCBS covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Obesity must NOT be restricted from coverage under the patient's benefit

Qualification pathways

You can qualify through any one of these.

Adult weight management (Wegovy)

All of:

  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient does NOT have Type 2 diabetes
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient is an adult (> 18 years of age)
  • BMI ≥ 35 kg/m2 with at least one comorbidity (e.g., hypertension, OSA, CVD, dyslipidemia)
  • Weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for minimum 6 months (documentation required within last 6 months)
  • Baseline weight and BMI obtained during in-office visit within last 30 days
  • Active participation in in-person, digital, or telehealth weight management program
  • Patient starting therapy OR has achieved and maintained weight loss ≥ 5% from baseline
  • Will NOT use in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to requested agent
  • Currently on low-calorie diet, increased physical activity, and behavioral modifications

Plus any one of:

  • Patient has NOT tried a targeted weight loss agent (e.g., Saxenda, Wegovy, Zepbound) in the past 12 months
  • Patient has tried a targeted weight loss agent in the past 12 months AND prescriber anticipates success with repeating therapy
  • Inadequate response to 3-month trial of liraglutide (Saxenda generic) not expected to occur with Wegovy
  • Intolerance or hypersensitivity to liraglutide (Saxenda generic) not expected to occur with Wegovy
  • FDA labeled contraindication to liraglutide (Saxenda generic) not expected to occur with Wegovy

Pediatric weight management (Wegovy, ages 12 to <18)

All of:

  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient does NOT have Type 2 diabetes
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient is pediatric (12 to less than 18 years of age)
  • Weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for minimum 6 months (documentation required within last 6 months)
  • Baseline weight and BMI obtained during in-office visit within last 30 days
  • Active participation in in-person, digital, or telehealth weight management program
  • Patient starting therapy OR has achieved and maintained BMI reduction ≥ 5% from baseline
  • Will NOT use in combination with another weight loss agent
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to requested agent
  • Currently on low-calorie diet, increased physical activity, and behavioral modifications

Plus any one of:

  • BMI ≥ 95th percentile for age and sex
  • BMI ≥ 30 kg/m2
  • BMI ≥ 85th percentile for age and sex AND at least one weight-related comorbidity/risk factor (e.g., hypertension, dyslipidemia, T2DM, OSA)
  • Patient has NOT tried a targeted weight loss agent in the past 12 months
  • Patient has tried a targeted weight loss agent in the past 12 months AND prescriber anticipates success with repeating therapy
  • Inadequate response to 3-month trial of liraglutide (Saxenda generic) not expected to occur with Wegovy
  • Intolerance or hypersensitivity to liraglutide (Saxenda generic) not expected to occur with Wegovy
  • FDA labeled contraindication to liraglutide (Saxenda generic) not expected to occur with Wegovy

Documentation to bring

  • Documentation that obesity is NOT restricted from coverage under patient's benefit
  • Documentation confirming patient does NOT have Type 2 diabetes
  • Baseline weight and BMI from in-office visit within the last 30 days
  • Documentation of active participation in lifestyle changes within last 6 months (e.g., food diary, exercise log, step counter report, gym attendance log, fitness tracker printout)
  • Medical records confirming active participation in in-person, digital, or telehealth weight management program
  • Medical records supporting prior liraglutide (Saxenda generic) trial (inadequate response, intolerance, or contraindication) OR documentation that patient has not tried a targeted weight loss agent in past 12 months OR documentation supporting repeat therapy with prescriber anticipation of success
  • MedWatch form if intolerance/hypersensitivity to liraglutide is the reason for step-through

Quantity limits

  • 0.25mg, 0.5mg, 1mg — 8 pens per 180 days (84-day)
  • 1.7mg, 2.4mg — 4 pens per 28 days

Approval and renewal

  • Initial approval: 3 months
  • Renewal: every 6 months
  • Renewal: At least 5% reduction in BMI.
  • Renewal: Adult: weight loss ≥ 5% from baseline OR weight loss ≥ 1 lb/week from baseline; AND baseline BMI ≥ 35 and current BMI ≥ 35 (measured within last 30 days). Pediatric (12-17): BMI reduction ≥ 5% from baseline AND current BMI ≥ 85th percentile for age and sex. Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required.

Not covered when

  • Type 2 diabetes (T2DM patients excluded from weight loss indication)
  • Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Concomitant use with another GLP-1 receptor agonist
  • Any FDA labeled contraindications to the requested agent

Policy note: Quantity limits for 0.25mg, 0.5mg, and 1mg are 8 pens per 180 days supply. Quantity limits for 1.7mg and 2.4mg are 4 pens per 28 days. Initial approval duration is 3 months for obesity indication. Renewal approval is 6 months. Step-therapy requires prior liraglutide (Saxenda generic) trial OR documented intolerance/contraindication. Policy title is 'GLP-1 Agonist for Non-Diabetic Use.' For renewal: adult continuation requires weight loss ≥ 5% from baseline OR ≥ 1 lb/week, AND baseline BMI ≥ 35 with current BMI ≥ 35 (within 30 days). Failed continuation criteria precludes future coverage of same drug.

verified June 5, 2026 · source: GLP-1 For Non Diabetic Use · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV risk reduction (Wegovy) — initial

All of:

  • Requested use is to reduce risk of MACE (CV death, non-fatal MI, non-fatal stroke) in adults with established CVD and obesity or overweight
  • Established CVD defined as CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm, all of atherosclerotic origin
  • Requested agent is FDA labeled for the requested indication and route of administration (Wegovy)
  • BMI ≥ 27 kg/m2
  • Patient will use optimized pharmacotherapy for established CVD in combination with requested agent
  • Patient is partaking in a heart healthy diet
  • Patient is engaging in physical activity at their level of ability
  • Patient will continue above lifestyle modifications while on therapy
  • Documentation required
  • Will NOT use in combination with another weight loss agent
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to requested agent
  • Currently on low-calorie diet, increased physical activity, and behavioral modifications

Plus any one of:

  • History of myocardial infarction
  • History of stroke
  • History of peripheral artery disease (intermittent claudication with ankle-brachial index < 0.85 at rest, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease)
  • Patient is currently a non-smoker (has not smoked in past 6 months)
  • Patient is on a smoking cessation plan (documentation required)

Documentation to bring

  • Documentation of established cardiovascular disease (CAD, ACS, MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid/arterial stenosis, or PAD)
  • Documentation of qualifying CVD event: history of MI, stroke, or PAD (with ABI < 0.85, revascularization, or amputation due to atherosclerotic disease)
  • Documentation of BMI ≥ 27 kg/m2
  • Documentation of current use of optimized pharmacotherapy for established CVD
  • Documentation of non-smoker status (no smoking in past 6 months) OR smoking cessation plan
  • Documentation of participation in heart healthy diet and physical activity

Quantity limits

  • 0.25mg, 0.5mg, 1mg — 8 pens per 180 days (84-day)
  • 1.7mg, 2.4mg — 4 pens per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Patient must have had clinical benefit with the requested agent. Continued use of optimized pharmacotherapy for established CVD required. T2DM exclusion and BMI/CVD event requirements are NOT re-verified at renewal — only clinical benefit and continued GDMT use are checked.

Not covered when

  • Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Concomitant use with another GLP-1 receptor agonist
  • Any FDA labeled contraindications to the requested agent

Policy note: Established CVD is broadly defined in this policy to include CAD, ACS, MI, stable/unstable angina, coronary/arterial revascularization, prior PCI/CABG, stroke, TIA, carotid/arterial stenosis, and PAD (including aortic aneurysm), all of atherosclerotic origin. Smoking cessation requirement: patient must be non-smoker (not smoked in past 6 months) OR on a smoking cessation plan. Initial approval 6 months. Renewal 6 months. No diabetes exclusion stated for this indication in the policy criteria (unlike weight loss pathway which explicitly excludes T2DM).

verified June 5, 2026 · source: GLP-1 For Non Diabetic Use · View policy document (PDF)

Open on its own page →

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

MASH with F2/F3 fibrosis (Wegovy)

All of:

  • Diagnosis of noncirrhotic NASH or MASH (medical records required)
  • Stage F2 or F3 fibrosis confirmed by BOTH: (1) FIB-4 score consistent with F2 or F3 fibrosis adjusted for age AND (2) one confirmatory test (liver biopsy, VCTE/FibroScan, ELF score, or MRE)
  • Requested agent is Wegovy
  • Patient is an adult (≥ 18 years of age)
  • Patient is being monitored and/or treated for any comorbid conditions (e.g., CVD, diabetes, dyslipidemia, hypertension)
  • Patient does NOT have decompensated cirrhosis
  • Patient does NOT have moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Patient does NOT have any other liver disease (e.g., Wilson's disease, HCC, hepatitis)
  • Prescriber is a specialist (hepatologist, gastroenterologist) OR has consulted with such a specialist
  • Will NOT use in combination with another weight loss agent
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to requested agent
  • Currently on low-calorie diet, increased physical activity, and behavioral modifications

Plus any one of:

  • BMI > 25 kg/m2
  • BMI > 23 kg/m2 if patient is of South Asian, Southeast Asian, or East Asian descent
  • If female: alcohol consumption < 20 grams/day
  • If male: alcohol consumption < 30 grams/day

Documentation to bring

  • Medical records confirming diagnosis of noncirrhotic NASH or MASH
  • FIB-4 score consistent with stage F2 or F3 fibrosis (adjusted for age)
  • One of the following confirming F2 or F3 fibrosis: liver biopsy, vibration-controlled transient elastography (VCTE/FibroScan), Enhanced Liver Fibrosis (ELF) score, or magnetic resonance elastography (MRE)
  • Documentation of patient BMI (> 25 kg/m2, or > 23 kg/m2 for South/Southeast/East Asian patients)
  • Documentation of alcohol consumption (< 20 g/day female, < 30 g/day male)
  • Documentation confirming absence of decompensated cirrhosis, Child-Pugh B/C, and other liver diseases
  • Documentation of monitoring/treatment for comorbid conditions (CVD, diabetes, dyslipidemia, hypertension)
  • Documentation of specialist involvement (hepatologist or gastroenterologist) or consultation

Quantity limits

  • 0.25mg, 0.5mg, 1mg — 8 pens per 180 days (84-day)
  • 1.7mg, 2.4mg — 4 pens per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Patient must have clinical benefit with the requested agent. Alcohol limits (< 20 g/day female, < 30 g/day male) re-verified at renewal. Absence of decompensated cirrhosis, Child-Pugh B/C, and other liver disease re-verified. Specialist requirement re-verified. Fibrosis staging and BMI are NOT re-verified at renewal.

Not covered when

  • Decompensated cirrhosis
  • Moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Any other liver disease (e.g., Wilson's disease, hepatocellular carcinoma, hepatitis)
  • Alcohol consumption ≥ 20 g/day (female) or ≥ 30 g/day (male)
  • Concomitant use with another weight loss agent
  • Concomitant use with another GLP-1 receptor agonist
  • Any FDA labeled contraindications to the requested agent

Policy note: Fibrosis must be confirmed by BOTH a FIB-4 score consistent with F2/F3 AND at least one of: liver biopsy, VCTE, ELF score, or MRE. Asian BMI threshold is > 23 kg/m2 for South Asian, Southeast Asian, or East Asian patients. One standard alcoholic drink contains roughly 14 grams of pure alcohol. Initial approval is 6 months (all non-obesity indications). Renewal is 6 months.

verified June 5, 2026 · source: GLP-1 For Non Diabetic Use · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Horizon BCBS has separate Wegovy policies that don't depend on that benefit:

Questions people ask
Does Horizon BCBS cover Wegovy?
It depends on your benefits. Horizon BCBS covers Wegovy for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Wegovy approval last with Horizon BCBS?
Weight Loss — Applies to Employer plans. Initial approval: 3 months. Renewal: every 6 months. Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 6 months. Renewal: every 6 months. Liver Disease (MASH) — Applies to Employer plans. Initial approval: 6 months. Renewal: every 6 months.
What does Horizon BCBS require to renew Wegovy?
Weight Loss — Applies to Employer plans. At least 5% reduction in BMI. Adult: weight loss ≥ 5% from baseline OR weight loss ≥ 1 lb/week from baseline; AND baseline BMI ≥ 35 and current BMI ≥ 35 (measured within last 30 days). Pediatric (12-17): BMI reduction ≥ 5% from baseline AND current BMI ≥ 85th percentile for age and sex. Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required. Heart Disease Risk Reduction — Applies to Employer plans. Patient must have had clinical benefit with the requested agent. Continued use of optimized pharmacotherapy for established CVD required. T2DM exclusion and BMI/CVD event requirements are NOT re-verified at renewal — only clinical benefit and continued GDMT use are checked. Liver Disease (MASH) — Applies to Employer plans. Patient must have clinical benefit with the requested agent. Alcohol limits (< 20 g/day female, < 30 g/day male) re-verified at renewal. Absence of decompensated cirrhosis, Child-Pugh B/C, and other liver disease re-verified. Specialist requirement re-verified. Fibrosis staging and BMI are NOT re-verified at renewal.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Horizon BCBS: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Independence Blue Cross, BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Louisiana, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota

All insurance plans · All medications

Summary of Horizon BCBS's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.